Literature DB >> 16627760

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Christian Flotho1, Elaine Coustan-Smith, Deqing Pei, Shotaro Iwamoto, Guangchun Song, Cheng Cheng, Ching-Hon Pui, James R Downing, Dario Campana.   

Abstract

In childhood acute lymphoblastic leukemia (ALL), early response to treatment is a powerful prognostic indicator. To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment. After excluding genes associated with genetic subgroups, we identified 17 genes that were significantly associated with MRD. The caspase 8-associated protein 2 (CASP8AP2) gene was studied further because of its reported role in apoptosis and glucocorticoid signaling. In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD, low levels of CASP8AP2 expression predicted a lower event-free survival (P = .02) and a higher rate of leukemia relapse (P = .01) and were an independent predictor of outcome. High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis. We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy. Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627760      PMCID: PMC1895863          DOI: 10.1182/blood-2006-01-0322

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Authors:  E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

Review 2.  Determination of minimal residual disease in leukaemia patients.

Authors:  Dario Campana
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 3.  Minimal residual disease in leukaemia patients.

Authors:  T Szczepański; A Orfão; V H van der Velden; J F San Miguel; J J van Dongen
Journal:  Lancet Oncol       Date:  2001-07       Impact factor: 41.316

4.  Tumor necrosis factor alpha receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators.

Authors:  Tomoshige Kino; George P Chrousos
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

5.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.

Authors:  Sanne Lugthart; Meyling H Cheok; Monique L den Boer; Wenjian Yang; Amy Holleman; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Gritta E Janka-Schaub; Rob Pieters; William E Evans
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

Authors:  E Coustan-Smith; F G Behm; J Sanchez; J M Boyett; M L Hancock; S C Raimondi; J E Rubnitz; G K Rivera; J T Sandlund; C H Pui; D Campana
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

Review 7.  Childhood acute lymphoblastic leukaemia--current status and future perspectives.

Authors:  C H Pui; D Campana; W E Evans
Journal:  Lancet Oncol       Date:  2001-10       Impact factor: 41.316

8.  Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival.

Authors:  Sabina Chiaretti; Xiaochun Li; Robert Gentleman; Antonella Vitale; Marco Vignetti; Franco Mandelli; Jerome Ritz; Robin Foa
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

9.  Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.

Authors:  R Trueworthy; J Shuster; T Look; W Crist; M Borowitz; A Carroll; L Frankel; M Harris; H Wagner; M Haggard
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Jose Sancho; Frederick G Behm; Michael L Hancock; Bassem I Razzouk; Raul C Ribeiro; Gaston K Rivera; Jeffrey E Rubnitz; John T Sandlund; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

View more
  39 in total

1.  Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Authors:  Johan Jansson; Yu-Chiao Hsu; Igor I Kuzin; Andrew Campbell; Craig A Mullen
Journal:  Leuk Res       Date:  2010-11-12       Impact factor: 3.156

Review 2.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

3.  Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].

Authors:  Deepa Bhojwani; Huining Kang; Renee X Menezes; Wenjian Yang; Harland Sather; Naomi P Moskowitz; Dong-Joon Min; Jeffrey W Potter; Richard Harvey; Stephen P Hunger; Nita Seibel; Elizabeth A Raetz; Rob Pieters; Martin A Horstmann; Mary V Relling; Monique L den Boer; Cheryl L Willman; William L Carroll
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

Review 4.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

5.  Solution NMR structures of homeodomains from human proteins ALX4, ZHX1, and CASP8AP2 contribute to the structural coverage of the Human Cancer Protein Interaction Network.

Authors:  Xianzhong Xu; Surya V S R K Pulavarti; Alexander Eletsky; Yuanpeng Janet Huang; Thomas B Acton; Rong Xiao; John K Everett; Gaetano T Montelione; Thomas Szyperski
Journal:  J Struct Funct Genomics       Date:  2014-06-19

6.  Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia.

Authors:  Yanyan Mei; Zhigang Li; Yi Zhang; Weiling Zhang; Huimin Hu; Pinwei Zhang; Minyuan Wu; Dongsheng Huang
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 7.  Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining.

Authors:  Paul S Gaynon
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 8.  High-risk childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Scott C Howard; Ching-Hon Pui
Journal:  Clin Lymphoma Myeloma       Date:  2009

9.  SUMO regulates proteasome-dependent degradation of FLASH/Casp8AP2.

Authors:  Astrid Vennemann; Thomas G Hofmann
Journal:  Cell Cycle       Date:  2013-05-13       Impact factor: 4.534

10.  A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.

Authors:  Christian Flotho; Elaine Coustan-Smith; Deqing Pei; Cheng Cheng; Guangchun Song; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2007-04-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.